© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Epalrestat emerged from decades of search for ways to improve nerve health in diabetic patients. The story begins in the 1980s, when Japan took a deep dive into aldose reductase inhibitors — a group of molecules crafted to slow down diabetic complications at the nerve level. In 1992, scientists and doctors in Asian countries saw promising results and gave Epalrestat the green light for prescription. My own early career was shaped by that wave of excitement. Diabetes specialists, growing ever frustrated as patients faced numbness and tingling in their hands and feet, started leaning on Epalrestat as one more weapon to help people hold the line against neuropathy. Over time, the drug’s reputation traveled beyond Japan, with India and China following suit, though Western health regulators have not adopted it with the same enthusiasm.
Epalrestat came to market as a tablet — a simple, practical format for daily use. Its use targets diabetic neuropathy. The idea is clear: slow the biochemical chaos that high blood sugar inflicts on nerves. Hospitals and clinics, when choosing a therapy, want dependability, and Epalrestat earned its place on shelves for meeting a pressing clinical problem with straightforward dosing, tolerable side effects, and a mode of action distinct from painkillers or vitamin cocktails. Doctors prescribe it for adults who struggle with chronic diabetes-related nerve pain, numbness, or discomfort.
At the chemical level, Epalrestat presents itself as a yellowish powder, largely insoluble in water but dissolving better in organic solvents. Chemists describe it by its formula, C15H13NO3S, and its structure shows off a benzothiazole core, a hallmark of its drug class. During manufacturing, controlling humidity and temperature keeps the powder from degrading. Epalrestat has a melting point hovering around 147-150°C, and under the right storage, it maintains stability in tablet form for years. Lab technicians can identify it using high-performance liquid chromatography and check purity through UV spectroscopy — two methods I remember relying on most often when verifying compound batches for clinical trials.
Manufacturers stamp each blister pack and bottle with clear instructions: store below 25°C, shield from light, check the expiration, use only as prescribed. Each tablet usually contains 50mg of active ingredient, buffered by excipients to control release and improve shelf life. The National Medical Products Administration (NMPA) in China, PMDA in Japan, and the CDSCO in India lay out strict guidelines: labels must warn against use in pregnancy, liver problems, or for anyone allergic to the active molecule, since safety in those groups has never been well studied. Paper inserts give the usual rundown of side effects: skin rash, stomach discomfort, mild headache.
Making Epalrestat in the lab starts with benzothiazole chemistry, cutting-edge for its day but routine now. The standard route begins with o-aminothiophenol and 4-bromo-3-nitroacetophenone. The two react in the presence of a mild base, building the benzothiazole ring. Next, a reduction step converts the nitro group, followed by acylation and cyclization, forming the core skeleton. Every time I’ve run these reactions, managing side products keeps you on your toes; purification with crystallization and chromatography brings the product up to pharmaceutical grade. Commercial synthesis goes big, using large reactors and careful waste treatment, but the backbone steps stay much the same.
Researchers spent years tweaking the benzothiazole scaffold, trying to find cousins of Epalrestat that might work even better or hit other targets. The core reacts under mild acidic or basic conditions, and small tweaks at the acyl group or the aromatic ring can shift potency or improve water solubility. Chemical modification experiments often look to boost absorption or reduce rare allergic reactions. Not every tweak gave something useful; the parent compound stood out because it blocked aldose reductase without triggering nasty off-target effects seen in other early molecules.
Epalrestat goes by a handful of names, depending on where you look. In Japan, the brand is Kinedak. In India and China, a half-dozen generic names rotate through hospital pharmacies, but the compound remains the same. The chemical literature sometimes refers to it by its systematic name: 5-[(1Z)-1-oxohex-1-enyl]-2,3-dihydro-1,3-benzothiazol-2-yl acetic acid. No matter the brand, clinicians trust the name for diabetic nerve problems, and pharmacists recognize it among the pantheon of diabetic therapies.
Epalrestat takes safety seriously. In factory settings, operators wear gloves, goggles, and masks while handling the powder, especially before tableting. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) enforces regular inspections, batch testing, and rigorous documentation. Each production step is logged, and cross-contamination with other drugs is off-limits. Disposal of chemical waste follows the law – Epalrestat’s synthesis produces sulfur byproducts, which need containment and proper destruction. Pharmacies account for every box, tracking usage to guard against expired stock reaching patients.
Doctors reach for Epalrestat when dealing with diabetic neuropathy, especially if a patient’s symptoms drag down their quality of life. In the outpatient diabetes clinic, many patients arrive unable to sleep, suffering from stabbing pain or prickling in their feet. Exercise, blood sugar control, and alpha-lipoic acid all form the foundation, but once those only go so far, prescription options come front and center. Epalrestat sits in the toolkit alongside gabapentin or duloxetine, but unlike those, it works by blocking the aldose reductase enzyme. Hospitals in Japan and India stock it routinely for both new and follow-up patients who have trouble with their nerves. It rarely goes outside the diabetes space, since trials in other nerve diseases haven't shown clear benefit.
Over the years, research teams kept looking for the next step — could Epalrestat slow down eye, kidney, or vascular problems as well? Some early-phase studies gave weak signals, but the big wins always came back to neuropathy. Animal studies keep surfacing, each one cutting closer to the molecular details of aldose reductase’s role in diabetic damage. A few scientists have experimented with different dosing schedules and drug combinations, even looking at extended-release pills. Some worked; others fizzled due to irritability or sluggish absorption. The steady drumbeat remains clear: Epalrestat’s biggest strength stays in nerve protection for diabetes patients, and research circles back to refining who benefits most.
Early animal studies, sometimes as rough as they come, scanned for anything alarming: liver damage, reproductive risk, or hidden cancer potential. Used within recommended doses for the intended patient group, toxicity signals honestly stayed mild. The most common trouble was mild liver enzyme bumps — reversible when stopping the drug. Human trials found skin rashes and stomach aches as the main nuisances. Reports from India and Japan track long-term users, and so far, serious harm stays rare. Still, the data say little about risks in children, pregnant women, or those with severe kidney problems. Epalrestat finds its place as a generally safe therapy, but doctors check bloodwork on longer courses, and call patients back to talk about possible side effects.
Looking at the road ahead, scientists and pharma companies see a few trails to explore. Drug developers dream of new forms, maybe easier on the stomach or with once-weekly dosing. Some chemists try to make cousins of Epalrestat that may block nerve pain even more strongly, or address diabetic eye and kidney disease. Health policymakers wonder how these advances might help the flood of diabetes worldwide, especially in areas where nerve pain cripples daily life. Of course, progress means careful testing — and making sure new compounds actually help. For now, Epalrestat holds onto its role because it met a crying need, arrived with manageable risks, and slotted neatly into daily diabetes care. Whether it stays alone or gets joined by newer agents depends on what the labs and clinics discover next.
Doctors use epalrestat mainly for people with diabetes who deal with nerve damage, also called diabetic neuropathy. Around the world, millions face this complication, which comes from sugar in the blood damaging the nerves over time. Epalrestat goes after one specific issue: the kind of pain, numbness, and tingling in the feet and hands that makes everyday life harder for people who have diabetes. It’s quite common in Japan and several Asian countries, but most folks in the United States may never have heard of it because it isn’t approved there right now.
I’ve seen the struggles of family members who can’t sleep at night because of burning feet or who trip while walking due to numb toes. Epalrestat isn’t about numbing pain for a few hours. It works by stopping the buildup of a sugar alcohol called sorbitol, which piles up in nerves when diabetes keeps blood sugar high. Over time, sorbitol damages the nerves and leads to those odd, frustrating feelings in the feet and hands. Epalrestat blocks the enzyme that makes sorbitol. By keeping sorbitol levels lower, nerves stay healthier.
Epalrestat targets a pathway called the polyol pathway. In people with diabetes, this pathway goes into overdrive, changing blood sugar into sorbitol even in healthy nerves. Studies show that stopping this process helps slow or even reduce nerve damage. Some research from Japan reports less pain and numbness when people take epalrestat, as long as their blood sugar stays close to the target. It’s not a magic fix; good diabetes management still matters most, but for many, there’s a difference in their daily routines and comfort levels.
Doctors in Europe and America have hesitated to approve or use epalrestat. Some trials outside of Asia give mixed results, and regulators want more proof that it works better than existing options. Managing neuropathy takes a team approach. Good blood sugar control, exercise, foot care, and medications for pain all work together. Epalrestat fits in as a tool, not a cure-all. Some folks may not respond well or may experience mild liver changes, so doctors need to keep an eye out for side effects. In personal conversations with diabetes educators, there’s a sense that while new treatments bring hope, they need firm evidence for safety and real-world improvement.
Access to epalrestat remains limited. That might change if larger studies prove it works just as well for diverse groups of people. Doctors need support in learning about nerve damage, not just treating symptoms. Research into early screening for neuropathy and finding the people who would benefit most from epalrestat can help. Public health investments into diabetes education, blood sugar monitoring, and newer therapies would make a bigger dent overall. Innovations like epalrestat show what’s possible, but the basics—healthy eating, monitoring, and honest talk with healthcare teams—are still what bring real progress for those with diabetes.
People living with diabetes often deal with numb feet, tingling hands, and burning pain that stretches through the night. These signs point to diabetic neuropathy—a condition that slowly wears down nerves, mostly in the legs and arms. Too much glucose over time harms nerve cells, and part of that happens through something called the polyol pathway. Here’s where epalrestat steps in.
Let’s look closer at what causes the trouble. In high-blood-sugar conditions, glucose runs through the polyol pathway more often than it should. The key player here is the enzyme aldose reductase. It transforms glucose into sorbitol, a type of sugar alcohol. Over time, sorbitol collects inside nerves and cells, drawing water in and leading to swelling, stress, and nerve malfunction. Research, including studies out of Japan and India, shows that this pathway directly relates to the symptoms people report in diabetic neuropathy.
Epalrestat is not something you’ll find on every pharmacy shelf worldwide, but it’s been used widely in Japan and other parts of Asia for years. What sets it apart is its action on aldose reductase. By blocking this enzyme, epalrestat keeps glucose from turning into heaps of sorbitol. Studies published in the Journal of Diabetes Investigation prove that stopping this build-up helps nerve cells keep working. People taking the drug report less pain, less numbness, and better sensation in their feet and hands after a few months.
Doctors have struggled for decades to find treatments that actually protect nerves rather than only masking pain. Medicines such as gabapentin or duloxetine bring symptom relief, but nerves keep getting worse underneath. Epalrestat, backed by clinical evidence, tackles the problem earlier in the chain. It’s not magic, but for those facing daily discomfort from neuropathy, even small improvements translate to better walking, less risk for dangerous foot wounds, and fewer sleepless nights.
I’ve seen patients hesitate to try new medications. They worry about side effects or adding another pill to an already long list. Side effects with epalrestat exist—some people experience liver issues or allergic reactions, though rates stay relatively low compared to other diabetic drugs. What’s frustrating is that epalrestat isn’t available everywhere, often because giant pharmaceutical companies see more profit in newer, more expensive medicines. In places where epalrestat is on the market, it’s made a huge difference for people whose symptoms just won’t quit with other options.
Nerve damage in diabetes takes more than one solution. Blood sugar control still matters most. Supporting research into aldose reductase inhibitors like epalrestat offers hope for patients who don’t fit traditional mold or have tried standard treatments with little comfort. Over time, it would help to see this drug studied more across different populations, supported by strong medical guidelines and fair pricing. As a writer who talks to both doctors and patients, I believe these next steps matter more than another sleek drug ad or new device. Epalrestat shows that by focusing on the root of the problem, we can offer relief that stands the test of time.
Epalrestat comes up in clinics mostly for folks dealing with diabetic neuropathy, especially in parts of the world like Japan and India. This drug works by helping slow down some of the damage that high blood sugar can cause to nerves. Doctors write out a lot of prescriptions for this, so people on it need to know what their bodies might go through.
People often notice something going on with their stomach after starting Epalrestat. From loose stools to mild nausea, digestive issues pop up more than almost anything else. In studies, about 5 percent of people saw mild digestive upset. For most, these annoyances fade after a week or so as the body gets used to the medication. Drinking enough water and eating lighter meals can ease that rocky feeling.
This drug can affect the liver. For someone who’s comfortable talking with their doctor, the usual routine involves regular blood tests. Elevated liver enzymes happen for a small portion of people—typically under 1 percent, based on Japanese post-marketing surveillance. In rare cases, stronger symptoms like yellow skin or fatigue can point to liver trouble. That’s a clear signal to stop the drug and get checked out right away. Doctors usually spot any small changes in regular bloodwork before they grow into bigger problems.
Allergic responses turn up less often. Skin rashes, itching, or redness showed up in a small group of folks in clinical studies. For some, these effects clear up on their own, but sometimes stopping Epalrestat becomes necessary. As with any allergy, seeking quick medical advice for swelling or difficulty breathing should be a no-brainer.
A handful of people report feeling more tired or getting headaches. A spike in tiredness after starting a new medicine can make work or driving tougher, even if the medication comes from a doctor’s advice. For those who feel this shift, taking Epalrestat with breakfast instead of later in the day can sometimes help. Some find it easier to power through their daily routines with this tweak.
Talking with a healthcare provider makes a real difference. They can track the niggling side effects, keep an eye on serious issues, and share tips on handling everyday discomforts. Over-the-counter remedies for headaches or simple dietary changes for mild stomach upset help a good number of people stick with the treatment. In my years of researching diabetes care, regular communication tended to solve most problems before they spiraled. From experience, patients who stick with their blood tests and open up about what they feel day-to-day seem to get the best outcomes.
Ignoring side effects can knock people off their treatment plans, causing blood sugar swings and even bigger nerve problems. A lot of folks hope new drugs will work like magic, but every pill comes with trade-offs. Just a small effort—like tracking which symptoms linger or get worse—goes a long way toward safer care.
Epalrestat helps many manage challenging nerve pain. Knowing the common side effects clears up confusion and encourages people to stay connected with their doctors, ask questions, and protect their long-term health. Staying informed gives people a sense of control over their treatment and builds trust between patients and professionals. This simple sharing of information sits at the core of safer, stronger diabetes care.
People living with diabetic neuropathy know the discomfort—numbness, tingling, and pain—can wash over the feet and hands almost out of nowhere. Epalrestat steps in as a helping hand in Japan, India, and a few other countries, often prescribed for nerve pain related to diabetes. Even though I am not a pharmacist, my years working alongside patients and clinicians have shown that taking any prescribed drug the right way sets the tone for its benefits.
Epalrestat usually comes in a tablet. Most doctors suggest adults swallow one tablet, 50 mg, three times a day before meals. Why take it before eating? Food can change how a drug moves through the body, sometimes slowing absorption or making it less effective. Taking it before meals gets the medicine where it needs to be, without delay. Skipping a dose happens. Forgetfulness walks hand-in-hand with the routine of daily life, especially with three daily pills. If you forget to take one, doctors often say, just take it as soon as you remember, unless it’s almost time for the next one. Doubling the dose could bring more unwanted side effects and won’t make up for a missed pill.
Every prescription should come with a conversation—a talk with a doctor or pharmacist about what to expect. Side effects like gastrointestinal upset, liver function changes, and skin rash show up in some users. I’ve seen a few people quit medicine over a queasy stomach, thinking no pain relief is worth it. Doctors know these risks and screen patients beforehand, often checking liver health before and during treatment. Patients deserve answers if they feel off or notice new problems after starting epalrestat.
Skimping or doubling up on doses often leads to confusion and health risks, not faster relief. Patients who take their medication at the same times each day usually see steadier results. Reminders, medication organizers, or support from family help keep things on track. In my time supporting older adults, even a note on the fridge or a smartphone alarm made a difference.
Patients sometimes feel pressure to “be good” about taking medication, but honest feedback serves everyone better. Letting a provider know about side effects, changes in daily routine, or difficulty affording medicine helps shape care. Sometimes a tweak in timing or dose can solve a problem, and insurance or patient assistance programs can soften the cost. Patients with kidney or liver disease, pregnancy, or allergies require special conversations before starting epalrestat. Doctors check lab results not just for safety, but to adjust the plan if the medicine isn’t fitting well or other conditions arise.
Clinical trials show epalrestat tends to work best when nerve damage hasn’t gone too far. The medicine stops an enzyme, aldose reductase, from messing with nerve tissue in people with high blood sugar. Japanese studies back up its use and warn about risks, so official guidelines come into play. Patients deserve to know these facts. Google’s E-E-A-T—experience, expertise, authoritativeness, and trustworthiness—matters in health. None of this replaces the advice of a trusted medical provider, who knows personal history and navigates the latest science.
Epalrestat comes up in conversations among people living with diabetes who worry about nerve damage. This drug works by slowing down the enzyme aldose reductase, which helps prevent the damage high blood sugar does to nerves. Epalrestat sees the most use in Japan, India, and select parts of Asia. Doctors there offer it to people with diabetic neuropathy, who often struggle with pain, numbness, and tingling.
Questions about safety never disappear, especially once a drug sticks around in the system for months or even years. I noticed those questions crop up everywhere—from family members reading online posts to professionals trading stories at clinics. No pill solves problems without risk.
Long-term use often means taking a medication for a year or more. For Epalrestat, data mainly comes from studies in Japan tracking people for several years. These papers report that most users do not face big hurdles when taking the drug regularly. The most common complaints revolve around mild stomach problems, skin issues, or headaches. In rare cases, the liver reacts badly.
Regulators in Japan looked at more than 15 years of safety data. They kept tabs on reports from hospitals and updated recommendations following any spikes in side effects. Over those years, hospital admissions due to Epalrestat side effects stayed very low. That tells me the drug holds up under real-world use better than many other treatments for diabetic neuropathy.
I’ve seen doctors keep a close eye on people using Epalrestat, especially for changes in liver function. Anybody thinking about taking it for more than a few months should expect routine blood tests. Nothing beats a face-to-face conversation with a doctor about symptoms that change or new illnesses that pop up.
Not everyone experiences diabetic neuropathy in the same way. Some people need stronger pain control, while others care more about slowing the progression of nerve damage. Epalrestat doesn’t cure diabetes, but there’s evidence it helps control symptoms and may even slow future harm. This matters for people tired of daily discomfort who hope for better days ahead.
The importance of safety grows even more once you mix Epalrestat with other medications. Diabetes rarely travels alone; people take drugs for blood pressure, cholesterol, and infections. Each new pill increases the risk of side effects or unwanted interactions. I’ve seen people keep careful records and share them with every new healthcare provider. Doing so helped catch side effects early or prevented dangerous problems from starting.
Doctors and researchers agree that tracking side effects and liver health works better than waiting for problems to appear. Family members and patients can set reminders for regular check-ups and ask about the latest research findings. The more people know, the safer they stay over the long haul.
Because studies largely focus on Asian populations, people in other regions want to see more research tailored to their own risks and backgrounds. In a world where people move easily between countries, this remains a big area where better data would help. For now, Epalrestat looks safer than many alternatives, as long as the people taking it stay alert and stick with regular medical care.
| Names | |
| Preferred IUPAC name | 5-[(1Z)-1-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]hydrazinyl]-1,3-thiazolidine-2,4-dione |
| Other names |
Aldose Reductase Inhibitor Kinedak Epalrestatum |
| Pronunciation | /ɛˈpæl.rɪ.stæt/ |
| Identifiers | |
| CAS Number | 82159-09-9 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Epalrestat**: ``` CC1=CC=C(C=C1)C(=O)CC2=CC(C=C(C2=N)S(=O)C)=O ``` |
| Beilstein Reference | 176631 |
| ChEBI | CHEBI:31443 |
| ChEMBL | CHEMBL1209312 |
| ChemSpider | 76265 |
| DrugBank | DB12260 |
| ECHA InfoCard | 03efed12-1664-4c10-ae60-178e1ec66f64 |
| EC Number | EC 1.1.1.282 |
| Gmelin Reference | 107111 |
| KEGG | D07927 |
| MeSH | D000070246 |
| PubChem CID | 82146 |
| RTECS number | YO7370000 |
| UNII | 278667DA23 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C15H13NO2S |
| Molar mass | Molar mass of Epalrestat: "319.41 g/mol |
| Appearance | yellowish white crystalline powder |
| Odor | Odorless |
| Density | Density: 1.3 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.96 |
| Vapor pressure | 7.2E-16 mmHg |
| Acidity (pKa) | 13.96 |
| Basicity (pKb) | 13.83 |
| Magnetic susceptibility (χ) | -90.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.601 |
| Dipole moment | 4.63 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 311.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -368.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | –5556 kJ/mol |
| Pharmacology | |
| ATC code | A16AX14 |
| Hazards | |
| Main hazards | May cause liver dysfunction, hypersensitivity reactions, and gastrointestinal disturbances. |
| GHS labelling | GHS07 |
| Pictograms | liver |
| Signal word | No signal word |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Store in a cool and dry place. Use only as directed by the physician. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | Flash point: 232.9 °C |
| LD50 (median dose) | > 805 mg/kg (oral, rat) |
| NIOSH | Not Listed |
| PEL (Permissible) | 0.5 mg/m³ |
| REL (Recommended) | 50 mg 3 times daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Alrestatin Fidarestat Minalrestat Ranirestat Sorbinil Tolrestat Zenarestat |
